Follow-up (days) |
623 (358 – 1061) |
621 (402 – 1035) |
649 (233 –
1140) |
0.540 |
Age (y) |
83.0 (77.0 – 87.0) |
83.0 (78.0 – 87.0) |
81.0 (77.0 –
82.0) |
0.077 |
Male |
96 (61.9%) |
86 (61.4%) |
10 (66.7%) |
0.691 |
BMI (kg/m²) |
25.9 (23.8 – 28.5) |
25.9 (23.8 – 28.5) |
25.7 (23.5 –
28.4) |
0.896 |
History of AF |
93 (60.0%) |
82 (58.6%) |
11 (73.3%) |
0.267 |
Indication for pacing |
|
|
|
|
High degree AV block
|
81 (52.3%)
|
72 (51.4%)
|
9 (60.0%)
|
0.432
|
Sick sinus syndrome
|
21 (13.5%)
|
18 (12.9%)
|
3 (20.0%)
|
|
AF with bradycardia
|
53 (34.2%)
|
50 (35.7%)
|
3 (20.0%)
|
|
Anticoagulation
|
103 (66.5%)
|
91 (65.0%)
|
12 (80.0%)
|
0.242
|
CHADS-VASc
|
4.0 (3.0 – 5.0)
|
4.0 (3.0 – 5.0)
|
4.0 (3.0 – 5.0)
|
0.421
|
Creatinine (mg/dL) |
1.11 (0.91 – 1.41) |
1.09 (0.89 – 1.39) |
1.37
(0.97 – 2.06) |
0.070 |
Renal function (eGFR, mL/min) |
60.7 (45.0 – 77.0) |
61.6 (46.0 –
77.0) |
50.1 (36.3 – 69.2) |
0.182 |
Dialysis |
8 (5.2%) |
5 (3.6%) |
3 (20.0%) |
0.006 |
LVEF (%) |
55.0 (53.0 – 60.0) |
55.0 (54.5 – 60.0) |
60.0 (56.3 –
60.0) |
0.052 |
Arterial hypertension |
111 (71.6%) |
99 (70.7%) |
12 (80.0%) |
0.448 |
Coronary artery disease |
54 (34.8%) |
49 (35.0%) |
5 (33.3%) |
0.898 |
COPD / pulmonary fibrosis |
16 (10.3%) |
14 (10.0%) |
2 (13.3%) |
0.687 |
Chronic cortisone use |
11 (7.1%) |
10 (7.1%) |
1 (6.7%) |
0.946 |
Diabetes Mellitus |
37 (23.9%) |
33 (23.6%) |
4 (26.7%) |
0.789 |
History of heart failure |
19 (12.3%) |
18 (12.9%) |
1 (6.7%) |
0.487 |
History of valve intervention |
49 (31.6%) |
39 (27.9%) |
10 (66.7%) |
0.002 |
History of pacemaker extraction due to infection |
13 (8.4%) |
12
(8.6%) |
1 (6.7%) |
0.800 |
Implant procedure duration (min) |
42.0 (36.0 – 58.0) |
43.0 (36.0 –
58.8) |
38.0 (33.0 – 50.0) |
0.261 |
Device redeployments during the implantation |
|
|
|
|
0 |
110 (71.0%) |
99 (70.7%) |
11 (73.3%) |
0.849 |
1 |
28 (18.0%) |
25 (17.9%) |
3 (20.0%) |
0.849 |
≥2 |
17 (11.0%) |
16 (11.4%) |
1 (6.7%) |
|